within Pharmacolibrary.Drugs.ATC.L;

model L04AJ01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1.0,
    Cl             = 0.005166666666666667,
    adminDuration  = 600,
    adminMass      = 0.9,
    adminCount     = 1,
    Vd             = 0.0055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Eculizumab is a monoclonal antibody that binds to complement protein C5, inhibiting terminal complement activation. It is used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), refractory generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. The drug is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) after intravenous infusion.</p><h4>References</h4><ol><li><p>Rajabally, YA (2022). Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome. <i>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</i> 19(3) 885–896. DOI:<a href=&quot;https://doi.org/10.1007/s13311-022-01253-4&quot;>10.1007/s13311-022-01253-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35648286/&quot;>https://pubmed.ncbi.nlm.nih.gov/35648286</a></p></li><li><p>Versino, F, &amp; Fattizzo, B (2024). Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. <i>International journal of laboratory hematology</i> 46 Suppl 1 43–54. DOI:<a href=&quot;https://doi.org/10.1111/ijlh.14281&quot;>10.1111/ijlh.14281</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38622956/&quot;>https://pubmed.ncbi.nlm.nih.gov/38622956</a></p></li><li><p>Yenerel, MN, et al., &amp; Szer, J (2023). Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up. <i>Advances in therapy</i> 40(1) 211–232. DOI:<a href=&quot;https://doi.org/10.1007/s12325-022-02339-3&quot;>10.1007/s12325-022-02339-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36272026/&quot;>https://pubmed.ncbi.nlm.nih.gov/36272026</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AJ01;
